Davis Capital Management
VIR icon

Davis Capital Management’s Vir Biotechnology VIR Stock Holding History

Davis Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$67 Hold
6
– – ﹤0.01% 1094
2026
Q2 		$61 Buy
+6
New +$57 ﹤0.01% 1171

Other funds holding VIR

Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Sierra Summit Advisors
Sierra Summit Advisors Incline Village, Nevada $852M AUM 73.11% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Raiffeisen Bank International
Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return
Louisiana State Employees Retirement System
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Virginia Retirement Systems
Virginia Retirement Systems Richmond, Virginia $16.3B AUM 35.33% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return
Amalgamated Bank
Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return

Davis Capital Management's VIR Position: Q3 2026 in Review

Davis Capital Management held its Vir Biotechnology (VIR) position steady in Q3 2026 at 6 shares worth $67. The position accounts for ﹤0.01% of the portfolio, ranked #1094.

Davis Capital Management first reported a position in VIR in Q2 2026 and has held it in 2 quarters since. 53 funds tracked by Wall St. Rank hold VIR as of Q3 2026.

  • Davis Capital Management held 6 shares of Vir Biotechnology worth $67 as of Q3 2026.
  • Davis Capital Management left its Vir Biotechnology share count unchanged in Q3 2026.
  • Vir Biotechnology made up ﹤0.01% of Davis Capital Management's portfolio in Q3 2026, its #1094 holding.
  • Davis Capital Management first reported a position in Vir Biotechnology in Q2 2026 and has held it in 2 quarters since.
  • 53 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2026.

Based on Davis Capital Management's 13F filing for Q3 2026, filed 8 Oct 2026.